WO2007025705A3 - Method for the generation of antigen-specific t-cells and uses thereof - Google Patents

Method for the generation of antigen-specific t-cells and uses thereof Download PDF

Info

Publication number
WO2007025705A3
WO2007025705A3 PCT/EP2006/008421 EP2006008421W WO2007025705A3 WO 2007025705 A3 WO2007025705 A3 WO 2007025705A3 EP 2006008421 W EP2006008421 W EP 2006008421W WO 2007025705 A3 WO2007025705 A3 WO 2007025705A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
specific
cells
generation
present
Prior art date
Application number
PCT/EP2006/008421
Other languages
French (fr)
Other versions
WO2007025705A2 (en
Inventor
Tim Greten
Firouzeh Korangy
Original Assignee
Hannover Med Hochschule
Tim Greten
Firouzeh Korangy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hannover Med Hochschule, Tim Greten, Firouzeh Korangy filed Critical Hannover Med Hochschule
Publication of WO2007025705A2 publication Critical patent/WO2007025705A2/en
Publication of WO2007025705A3 publication Critical patent/WO2007025705A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the generation and expansion of antigen-specific T-cells. Furthermore, the present invention relates to the use of antigen-specific T-cells obtained with the method according to the present invention in adoptive cell transfer therapy and in the treatment of various disorders and diseases including infections and cancer. Moreover, the present invention provides for kits and its use for generating and expanding antigen-specific T-cells. The present invention allows for the generation of antigen-specific T-cells suitable for adoptive cell transfer. The methods for the generation and expansion of antigen-specific T-cells include both in vitro and in vivo approaches.
PCT/EP2006/008421 2005-08-29 2006-08-29 Method for the generation of antigen-specific t-cells and uses thereof WO2007025705A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2005/009289 2005-08-29
PCT/EP2005/009289 WO2007025554A1 (en) 2005-08-29 2005-08-29 Method for the generation of antigen-specific t-cells and uses thereof

Publications (2)

Publication Number Publication Date
WO2007025705A2 WO2007025705A2 (en) 2007-03-08
WO2007025705A3 true WO2007025705A3 (en) 2007-05-18

Family

ID=35241189

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2005/009289 WO2007025554A1 (en) 2005-08-29 2005-08-29 Method for the generation of antigen-specific t-cells and uses thereof
PCT/EP2006/008421 WO2007025705A2 (en) 2005-08-29 2006-08-29 Method for the generation of antigen-specific t-cells and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009289 WO2007025554A1 (en) 2005-08-29 2005-08-29 Method for the generation of antigen-specific t-cells and uses thereof

Country Status (1)

Country Link
WO (2) WO2007025554A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014096015A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013095A2 (en) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013095A2 (en) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUDLEY M E ET AL: "Adoptive-cell-transfer therapy for the treatment of patients with cancer", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 3, no. 9, September 2003 (2003-09-01), pages 666 - 675, XP002353828, ISSN: 1474-175X *
GRETEN T F ET AL: "Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 271, no. 1-2, 20 December 2002 (2002-12-20), pages 125 - 135, XP004393932, ISSN: 0022-1759 *
MÄRTEN A ET AL: "Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 51, no. 1, March 2002 (2002-03-01), pages 25 - 32, XP002354938, ISSN: 0340-7004 *
OELKE M ET AL: "TECHNOLOGICAL ADVANCES IN ADOPTIVE IMMUNOTHERAPY", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 41, no. 1, January 2005 (2005-01-01), pages 13 - 21, XP009056991, ISSN: 0025-7656 *
OH SEONG-TAEK ET AL: "Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide", VACCINE, vol. 24, no. 15, April 2006 (2006-04-01), pages 2860 - 2868, XP002418807, ISSN: 0264-410X *

Also Published As

Publication number Publication date
WO2007025705A2 (en) 2007-03-08
WO2007025554A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
WO2007120811A3 (en) Hemangio-colony forming cells
CY1121799T1 (en) PYRIMIDE[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMAPOPOIETIC PROGENIC CELLS
WO2014186469A3 (en) Human application of engineered chimeric antigen receptor (car) t-cells
MX2021004775A (en) Expansion of tils utilizing akt pathway inhibitors.
EP1483281A4 (en) Methods for producing interfering rna molecules in mammalian cells and therapeutic uses for such molecules
WO2009058911A3 (en) Preparation and isolation of 5' capped mrna
BR0210599A (en) Use of carbon monoxide, method for maintaining an animal cell in vitro, article of manufacture as well as sterile cell medium
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
ATE505533T1 (en) ANTIGEN-PRESENTING CELLS, METHOD FOR THEIR PRODUCTION AND THEIR USE FOR CANCER VACCINES
WO2007080590A3 (en) Human embryonic stem cell-derived connective tissue progenitors for tissue engineering
TW200621801A (en) Antibody molecules having specificity for human IL-17
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
TW200633726A (en) Uses of mammalian cytokine; related reagents
EP1784639A4 (en) Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use
MY147217A (en) Antibody molecules having specificity for human il-06
CL2008002852A1 (en) Compounds derived from 7-fluoro-5-methyl-2- (phenylamino) -6,7,8,9-tetrahydro-5h-pyrimido [4,5-b] [1,4] diazepin-6 (7h) -one ; pharmaceutical composition comprising said compounds; and its use in the treatment of cancers, inflammation, alopecia, autoimmune, cardiovascular, infectious, nephrological, neurodfegenerative, skin and bone diseases.
WO2007120343A3 (en) Heat shock rna and its use
WO2010000127A9 (en) Method to induce and expand therapeutic alloantigen- specific human regulatory t cells in large-scale
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2009040413A3 (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2007136760A3 (en) Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
EP1805300A4 (en) Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair
WO2007022642A3 (en) Anti-inflammatory molecules and their uses
WO2006105255A3 (en) Cancer vaccines and therapeutic methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06805643

Country of ref document: EP

Kind code of ref document: A2